Demonstration of in vitro antagonism between fusidic acid and quinolones

Journal of International Medical Research

Volumn 30, Issue 5, 2002, Pages 525-528

  Ertek, M ^a   Yazgi, H ^a   Erol, S ^a   Altoparlak, U ^a  

^a ATATURK UNIVERSITY   (Turkey)

Author keywords

Antagonism; Antibiotics; Disk approximation test; Fusidic acid; In vitro; Quinolones

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; FUSIDIC ACID; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; HETEROCYCLIC COMPOUND; QUINOLINE DERIVATIVE; QUINOLONE DERIVATIVE;

ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; IN VITRO STUDY; NONHUMAN; PRESCRIPTION; SAMPLE; STAPHYLOCOCCUS; STAPHYLOCOCCUS INFECTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; CIPROFLOXACIN; FLUOROQUINOLONES; FUSIDIC ACID; HUMANS; MICROBIAL SENSITIVITY TESTS; OFLOXACIN; QUINOLINES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS;

EID: 0036753988     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000203000509     Document Type: Article

References (14)

1. Verbist L: The antimicrobial activity of fusidic acid. J Antimicrob Chemother 1990; 25 (Suppl B): 1-5.
2. Mandell LA: Fusidic acid. In: Principles and Practice of Infectious Diseases, 5th edn (Mandell GL, Bennett JE, Dilon R, eds). Philadelphia: Churchill Livingstone, 2000; pp306-307.
3. Van Der Auwera P, Godard C, Dennis C, De Maeyer S, Vanhoof R: In-vitro activities of new antimicrobial agents against multiresistant Staphylococcus aureus isolated from septicemic patients during a Belgian national survey from 1983-1985. Antimicrob Agents Chemother 1990; 34: 2260-2262.
4. Hooper DC: Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 2001; 32 (Suppl 1): S9-S15.
5. Roder BL, Gutschik E: In-vitro activity of ciprofloxacin combined with either fusidic acid rifampicin against aureus. J Antimicrob Chemother 1989; 23: 347-352.
6. Uri JV: Antibacterial antagonism between fusidic acid and ciprofloxacin. Acta Microbiologica Hung 1993; 40: 141-149.
7. Reeves DS: The pharmacokinetics of fusidic acid. J Antimicrob Chemother 1987; 20: 467-476.
8. Comite de l'Antibiogramme de la Societe Francaise de Microbiologie. Communique Path Biol 1996; 44: 1.
9. NCCLS: Performance Standards for Antimicrobial Susceptibility Testing, 11th Informational Supplement. NCCLS Document M100-S11. Wayne, PA: NCCLS, 2001.
10. Spangler SK, Jacobs MR, Appelbaum PC: Time-kill study of the activity of trovafloxacin compared with ciprofloxacin, sparfloxacin, metronidazole, cefoxitin, piperacillin and pipercillin/tazobactam against six anaerobes. J Antimicrob Chemother 1997; 39 (Suppl B): 23-27.
11. Visalli MA, Bajaksouzian S, Jacobs MR, Appelbaum PC: Synergistic activity of trovafloxacin with other agents against Gram-positive and -negative organisms. Diagn Microbiol Infect Dis 1998; 30: 61-64.
12. Li RC, Nix DE, Schentag JJ: Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors. J Chemother 1996; 8: 25-32.
13. Collignon P, Turnidge J: Fusidic acid in vitro activity. Int J Antimicrob Agents 199; 12 (Suppl 2): S45-S58.
14. Koneman EW, Allen SD, Janda WM, Schreckember PC, Win WC: Antimicrobial susceptibility testing. In: Diagnostic Microbiology, 4th edn. Philadelphia: JB Lippincott Co., 1992; pp609-668.